Improving outcomes: In ophthalmology via sustained drug delivery

ONdrugDelivery

Volumn , Issue 48, 2014, Pages 10-13

  Navratil, Tomas ^a   Maynor, Benjamin ^a   Yerxa, Benjamin ^a  

^a Envisia Therapeutics Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG CARRIER; POLYMER; PROSTAGLANDIN; VASCULOTROPIN; VASCULOTROPIN INHIBITOR;

ANTERIOR EYE CHAMBER; BIODEGRADABLE IMPLANT; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG IMPLANT; GLAUCOMA; HUMAN; INTRAOCULAR DRUG ADMINISTRATION; INTRAOCULAR PRESSURE; NONHUMAN; NOTE; OPHTHALMOLOGY; SUSTAINED DRUG RELEASE; TOPICAL TREATMENT;

EID: 84898452385     PISSN: 2049145X     EISSN: 20491468     Source Type: Trade Journal    
DOI: None     Document Type: Note

References (6)

1. Garcia A, Mack P, Williams S, Fromen C, Shen T, Tully J, Pillai J, Kuehl P, Napier M, Desimone JM, Maynor BW, "Microfabricated engineered particle systems for respiratory drug delivery and other pharmaceutical applications". J Drug Del, 2012, 941243.
2. Deepak S, Ahmad AA, "Glaucoma management: relative value & place in therapy of available drug treatments". Ther Adv Chronic Dis, 2014, Vol 5(1), pp 30-43.
3. Knight OJ, Lawrence SD, "Sustained drug delivery in glaucoma". Curr Opin Ophthalmol, 2014, Jan 23.
4. Zhou Z, Althin R, Sforzolini BS, Dhawan R, "Persistency and treatment failure in newly diagnosed open angle glaucoma patients in the United Kingdom". Br J Ophthalmol, 2004, Vol 88(11), pp 1391-4.
5. Schwartz SG, Scott IU, Flynn HW Jr, Stewart MW, "Drug delivery techniques for treating age-related macular degeneration". Drug Deliv, 2014, Vol 11(1), pp 61-8.
6. World Health Organization: VISION 2020 Action Plan 2006-2010 (http:// www.who.int/blindness/Vision2020_ report.pdf).